Collagen Matrix is now Regenity Biosciences
Paramus, NJ (March 29, 2023) – Collagen Matrix, Inc., a provider of regenerative medicine and a Linden Capital Partners (“Linden”) portfolio company, announced today it has changed its name to Regenity Biosciences (“Regenity”) and unveiled a new visual identity and website.
The company, which has been around for more than 25 years,, transforms bioresorbable materials into regenerative solutions to repair and regenerate tissue and bone for a variety of markets including dental, spine, orthopedic, neurosurgery, ENT and nerve repair. After first getting its start with collagen-based medical devices, the company has since introduced numerous bioresorbable technologies with more than 71 product lines commercially available globally. Most recently, Regenity expanded its product portfolio to include versatile bioresorbable polymer technologies via the acquisition of Polyganics, which was the impetus behind the new name and brand direction.
“Material transformation is at the core of everything we do and the inspiration behind our new name and rebrand,” said Shawn McCarthy, CEO of Regenity. “We recognize the urgency in the work we do because of how critical it is to patients. Regenity represents our commitment to making a material difference with what we believe are life-changing products, which support our vision to be the global leader in bioresorbable technologies for tissue and bone repair, as we now provide materials for the treatment of more than four million patients per year.”
Along with the new name and vision, Regenity is accelerating its innovation pipeline, mixing a build-it-now mentality with the development of new technology platforms and materials. The company is delivering the next generation of regenerative devices across an expanding range of clinical applications by introducing new synthetic polymers, and other complementary bioresorbable materials, to an already established product portfolio of collagen capabilities. Regenity now operates in five locations in the U.S. and the Netherlands, employing more than 275 associates worldwide.
Regenity will unveil its new name and brand at the Society for Biomaterials Annual Meeting in San Diego, held April 19 – April 22, 2023. The company will also be presenting three abstracts on the topics of osteostimulatory properties and in vivo evaluation of their novel bioactive bone graft substitute and novel in vitro models for studying damaged extracellular matrices. This data was generated through the company’s cell biology lab, which was opened in the spring of 2022. Visit Regenity at Booth #205 to learn more.
For more information, visit the new Regenity website at www.regenity.com and follow the company on LinkedIn @Regenity.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested in over 40 healthcare companies encompassing over 250+ total transactions. The firm has raised over $7 billion in limited partner commitments since inception. For more information, please visit www.lindenllc.com.